Spatiotemporal control of CRISPR/Cas9 gene editing

被引:0
作者
Chenya Zhuo
Jiabin Zhang
Jung-Hwan Lee
Ju Jiao
Du Cheng
Li Liu
Hae-Won Kim
Yu Tao
Mingqiang Li
机构
[1] Sun Yat-sen University,Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital
[2] Dankook University,Institute of Tissue Regeneration Engineering (ITREN)
[3] Sun Yat-sen University,Department of Nuclear Medicine, The Third Affiliated Hospital
[4] Sun Yat-sen University,PCFM Lab of Ministry of Education, School of Materials Science and Engineering
[5] Sun Yat-sen University,Department of Gynecology and Obstetrics, The Third Affiliated Hospital
[6] Guangdong Provincial Key Laboratory of Liver Disease Research,undefined
来源
Signal Transduction and Targeted Therapy | / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The clustered regularly interspaced short palindromic repeats (CRISPR)/associated protein 9 (CRISPR/Cas9) gene editing technology, as a revolutionary breakthrough in genetic engineering, offers a promising platform to improve the treatment of various genetic and infectious diseases because of its simple design and powerful ability to edit different loci simultaneously. However, failure to conduct precise gene editing in specific tissues or cells within a certain time may result in undesirable consequences, such as serious off-target effects, representing a critical challenge for the clinical translation of the technology. Recently, some emerging strategies using genetic regulation, chemical and physical strategies to regulate the activity of CRISPR/Cas9 have shown promising results in the improvement of spatiotemporal controllability. Herein, in this review, we first summarize the latest progress of these advanced strategies involving cell-specific promoters, small-molecule activation and inhibition, bioresponsive delivery carriers, and optical/thermal/ultrasonic/magnetic activation. Next, we highlight the advantages and disadvantages of various strategies and discuss their obstacles and limitations in clinical translation. Finally, we propose viewpoints on directions that can be explored to further improve the spatiotemporal operability of CRISPR/Cas9.
引用
收藏
相关论文
共 189 条
[1]  
Wilbie D(2019)Delivery aspects of CRISPR/Cas for in vivo genome editing Acc. Chem. Res. 52 1555-1564
[2]  
Wang HX(2017)CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery Chem. Rev. 117 9874-9906
[3]  
Song X(2021)Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy Adv. Drug Deliv. Rev. 168 158-180
[4]  
Lin P(2020)CRISPR-Cas13 inhibitors block RNA editing in bacteria and mammalian cells Mol. Cell 78 850-861
[5]  
Gallagher DN(2018)Repair of a site-specific DNA cleavage: old-school lessons for Cas9-mediated gene editing ACS Chem. Biol. 13 397-405
[6]  
Haber JE(2016)Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA Nat. Biotechnol. 34 339-344
[7]  
Richardson CD(2019)Precision control of CRISPR-Cas9 using small molecules and light Biochemistry 58 234-244
[8]  
Gangopadhyay SA(2019)Spatial control of in vivo CRISPR-Cas9 genome editing via nanomagnets Nat. Biomed. Eng. 3 126-136
[9]  
Zhu H(2019)Dual-locking nanoparticles disrupt the PD-1/PD-L1 pathway for efficient cancer immunotherapy Adv. Mater. 31 e1905751-740
[10]  
Zhang Z(2020)Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer Nat. Med. 26 732-457